Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login